Symptoms and General Pathology

All Conditions

Neoplasms

Rare Diseases

Recurrence

Glioblastoma

Astrocytoma

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Temozolomide

Bortezomib

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Antineoplastic Agents, Alkylating

Alkylating Agents

Therapy with temozolomide, bevacizumab and bortezomib

Escalating temozolomide with standard dose bevacizumab and bortezomib

Temozolomide, bevacizumab and bortezomib

Jeffrey J. Olson, MD

This is a single-center (Emory University), open-label, single arm, phase I study to assess safety and toxicity of bortezomib in combination with bevacizumab and escalating doses of temozolomide for patients with recurrent glioblastoma multiforme. Patients requiring anti-epileptic medications will have to be at least 10 days off EIAEDs. Only non-EIAEDs are accepted.

Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

Phase I Trial of Temozolomide, Bevacizumab Plus Bortezomib for Patients With Recurrent Glioblastoma Multiforme

Complete or partial responses will be based upon major changes in tumor size on the Gd-MRI scan compared to the baseline scan. Determination of progressive disease is based upon comparison to the previous scan with the smallest measurements.

Six month progression-free survival and overall survival of patients completing one cycle of the investigational therapy.

Schering-Plough

Genentech, Inc.

Millennium Pharmaceuticals, Inc.

Emory University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme	NCT01435395	Glioblastoma Mu...	Temozolomide, b...	18 Years -	Emory University
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme	NCT01435395	Glioblastoma Mu...	Temozolomide, b...	18 Years -	Emory University

Spots Global Cancer Trial Database for temozolomide, bevacizumab and bortezomib